多西他赛联合奈达铂治疗老年妇女复发性上皮性卵巢癌的临床研究  

Clinical investigation of docetaxel combined with nedaplatin in the treatment of ovarian cancer in elderly women

作　　者：崔颖[1] 周丹[1] 马琳琳[1] 申桂华[1] 

机构地区：[1]卫生部北京医院妇产科,100730

出　　处：《中华老年医学杂志》2013年第8期836-839,共4页Chinese Journal of Geriatrics

摘　　要：目的评价多西他赛联合奈达铂治疗老年妇女复发性上皮性卵巢癌的疗效和安全性。方法42例复发性上皮性卵巢癌老年患者应用多西他赛联合奈达铂化疗方案，多西他赛60～70mg／m2，第1天静脉滴注，奈达铂70-80mg／m2，第2天静脉滴注，3周重复，采用实体肿瘤治疗疗效评估标准（RECIST）和血清CA125水平进行疗效评估，不良反应依据WHO抗癌药物毒性表现及分级标准进行评价。结果42例老年患者中有4例患者因病情进展，完成2个疗程后改用其他方案，其余患者均完成4～6个疗程化疗。42例患者中完全缓解18例（42．9％），部分缓解10例（23．8％），病情稳定6例（14．3％），疾病进展8例（19．0％），中位疾病无进展生存时间7个月，有效率为66．7％（28／42）。不良反应发生率前3位依次为脱发、恶心呕吐、白细胞减少，患者均可接受或通过药物治疗缓解。结论多西他赛联合奈达铂方案治疗老年妇女铂类敏感及耐药复发性上皮性卵巢癌均有较好的疗效，不良反应发生率相对较低，安全性高，耐受性好。Objective To evaluate the efficacy and safety of concomitant docetaxal （DTX） and nedaplatin （NDP） therapy for recurrent epithelial ovarian cancer in elderly women. Methods Totally 42 elderly patients with histologically confirmed recurrent epithelial ovarian cancer received chemotherapy with DTX combined with NDP. DTX with the dose of 60-70 mg/m2 was administered intravenously on day 1, followed by NDP with the dose of 70-80 mg/m2 given intravenously on day 2. The treatment was repeated every 3 weeks. The efficacy was evaluated according to response evaluation criteria in solid tumors （RECIST） and serum CA125 level. Adverse reactions were assessed according to performance and standard criteria in toxicity of anticancer agents of WTO. Results 4 patients were switched to other chemotherapy strategies due to progression of disease after 2 courses of treament, and the other patients completed 4 to 6 courses. Among 42 patients, 18 cases （42.9G） showed complete remission, 10 cases （23.8G） showed partial remission, 6 cases （14.3G） were in stable conditions, and 8 cases （19.0G） progressed to severe disease. The median progression-free survival （PFS） time was 7 months, and the efficacy rate （complete and partial remission） was 66.7G （28/42）. The main adverse effects were alopecia, nausea and vomit, and leucopenia. Patients could get remission by receiving drug therapy. Conclusions Docetaxel plus nedapIatin therapy has a good therapeutic effect with low incidence of adverse reactions, high safety and well tolerance in elderly platinum-sensitive women and in those with platinum-resistant recurrent epithelial ovarian cancer.

关 键 词：卵巢肿瘤 抗肿瘤联合化疗方案 

分 类 号：R737.31[医药卫生—肿瘤]